A5019979707- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Systemic Sclerosis and Related Diseases
- Autoimmune and Inflammatory Disorders Research
- SARS-CoV-2 and COVID-19 Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Neurogenesis and neuroplasticity mechanisms
- Rheumatoid Arthritis Research and Therapies
- T-cell and B-cell Immunology
- Cytokine Signaling Pathways and Interactions
- Myasthenia Gravis and Thymoma
- Monoclonal and Polyclonal Antibodies Research
- Long-Term Effects of COVID-19
- MicroRNA in disease regulation
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Ocular Diseases and Behçet’s Syndrome
- Cell Image Analysis Techniques
- PI3K/AKT/mTOR signaling in cancer
- Retinal and Optic Conditions
- Neuroinflammation and Neurodegeneration Mechanisms
- Vasculitis and related conditions
University of Florence
2018-2025
Azienda Ospedaliero-Universitaria Careggi
2017-2025
Imperial College London
2020-2024
Regione Toscana
2022
Imperial College Healthcare NHS Trust
2021
King's College Hospital
2021
Barts Health NHS Trust
2021
Ospedale Policlinico San Martino
2021
University of Genoa
2021
Department of Medical Sciences
2021
To determine whether autologous hematopoietic stem cell transplantation (aHSCT) is able to induce durable disease remission in people with multiple sclerosis (MS), we analyzed the long-term outcomes after a large cohort of patients MS.To be included, minimum dataset (consisting age, MS phenotype, Expanded Disability Status Scale [EDSS] score at baseline, information on technology, and least 1 follow-up visit transplantation) was required.Two hundred ten were included (relapsing-remitting...
During the COVID-19 pandemic, myasthenia gravis (MG) patients have been identified as subjects at high risk of developing severe COVID-19, and thus were offered vaccination with priority. The lack direct data on safety tolerability SARS-CoV-2 vaccines in MG contributed to vaccine hesitancy. To address this issue, assessed a large cohort from two referral centers.Patients confirmed diagnosis, consecutively seen between October December 2021 centers, enrolled. Demographics, clinical...
<h3>Background and Objectives:</h3> Uncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). In this study we compared the effect of AHSCT other anti-inflammatory disease modifying therapies (DMT) on long-term disability worsening SPMS. <h3>Methods:</h3> We collected data from Italian-Bone-Marrow-Transplantation-Study-Group Italian-Multiple-Sclerosis-Register....
Natalizumab (NTZ) and autologous hematopoietic stem cell transplantation (AHSCT) are two successful treatments for relapsing-remitting multiple sclerosis (RRMS), an autoimmune T-cell-driven disorder affecting the central nervous system that is characterized by relapses interspersed with periods of complete or partial recovery. Both RRMS have been documented to impact T-cell subpopulations receptor (TCR) repertoire in terms clone frequency, but, so far, link between naive memory populations,...
To examine outcomes in people with multiple sclerosis (PwMS) treated autologous hematopoietic stem cell transplantation (AHSCT) a real-world setting.This was retrospective cohort study of PwMS AHSCT at 2 centers London, UK, consecutively between 2012 and 2019 who had ≥6 months follow-up or died any time. Primary were survival free (MS) relapses, MRI new lesions, worsening Expanded Disability Status Scale (EDSS) score. Adverse events rates also examined.The includes 120 PwMS; 52% progressive...
Abstract Background and purpose Effectiveness of autologous haematopoietic stem cell transplantation (AHSCT) in relapsing–remitting multiple sclerosis (MS) is well known, but secondary–progressive (SP)‐MS it still controversial. Therefore, AHSCT activity was evaluated SP‐MS using low‐dose immunosuppression with cyclophosphamide (Cy) as a comparative treatment. Methods In this retrospective monocentric 1:2 matched study, patients were treated intermediate‐intensity (cases) or intravenous...
Objective To compare clinical and radiological outcomes among relapsing multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT), alemtuzumab (ATZ), ocrelizumab (OCR). Methods From a London (UK) hospital‐based observational cohort, modeled data were obtained from 621 relapsing–remitting patients, who AHSCT (n = 103), ATZ 204), OCR 314), followed up for 43, 32 median months, respectively. The annualized relapse rate, new magnetic resonance imaging...
To quantify the probability that monthly intravenous (IV) and subcutaneous (SC) natalizumab (NTZ) had similar efficacy in relapsing-remitting multiple sclerosis (RRMS), non-inferiority of NTZ-SC versus NTZ-IV on combined MRI unique active lesions number (CUAL) was explored re-analysing REFINE data set. Non-inferiority margins were selected equal to 25%/33%/50% fractions effect size placebo observed AFFIRM study. Ninety-nine RRMS included. resulted not inferior CUAL for all at 2.5%...
Background and purpose Natalizumab ( NTZ ) is a highly effective treatment for relapsing‐remitting multiple sclerosis (MS), but its withdrawal often followed by disease reactivation or rebound, even if other disease‐modifying treatments DMT s) are administered. In this study, the first time, safety efficacy of autologous hematopoietic stem‐cell transplantation aHSCT performed following discontinuation were retrospectively compared with conventional s. Methods Patients MS treated who...
Background: Autologous haematopoietic stem cell transplantation (aHSCT) is a valuable option in aggressive relapsing–remitting multiple sclerosis (MS), but its efficacy secondary progressive (SP)-MS still controversial. Objective: Assessing of aHSCT SP-MS by clinical-radiological outcomes. Methods: Open-label monocentric retrospective study enrolling consecutive patients treated with BEAM-aHSCT the period 1999–2016. Results: In total, 26 moderate–severe disability were included....
Autologous haematopoietic stem cell transplantation (AHSCT) is highly effective in reducing new inflammatory activity aggressive multiple sclerosis (MS). A remarkable decrease of serum neurofilament light chains (sNfL) concentration, a marker axonal damage, was reported MS following high-intensity regimen AHSCT, but hints for potential neurotoxicity had emerged. sNfL and brain atrophy were therefore analysed cohort patients with treated intermediate-intensity exploring whether might be...
Drug-induced liver injury (DILI) is a potential adverse event of disease-modifying therapies (DMTs) for the treatment multiple sclerosis (MS), as well methylprednisolone pulsed therapy used in case MS relapse. DILI may be induced by different mechanisms, including idiosyncratic reaction, autoimmune hepatitis or viral reactivation. In patients receiving humanized anti-CD20 monoclonal antibody (mAb) ocrelizumab, has been rarely reported and was mostly associated with B virus (HBV) Here we...
Background Leptomeningeal enhancement (LME) is considered an MRI marker of leptomeningeal inflammation in inflammatory neurological disorders, including multiple sclerosis (MS). To our knowledge, no disease-modifying therapies (DMTs) have been demonstrated to affect LME number or morphology so far. Methods Monocentric study investigating the frequency and a cohort people with (pw)MS who performed 3 T brain standardized protocol (including post-contrast FLAIR sequence), exploring impact...